These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

532 related items for PubMed ID: 32699034

  • 1. Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial.
    Brunner HI, Abud-Mendoza C, Viola DO, Calvo Penades I, Levy D, Anton J, Calderon JE, Chasnyk VG, Ferrandiz MA, Keltsev V, Paz Gastanaga ME, Shishov M, Boteanu AL, Henrickson M, Bass D, Clark K, Hammer A, Ji BN, Nino A, Roth DA, Struemper H, Wang ML, Martini A, Lovell D, Ruperto N, Paediatric Rheumatology International Trials Organisation (PRINTO) and the Pediatric Rheumatology Collaborative Study Group (PRCSG).
    Ann Rheum Dis; 2020 Oct; 79(10):1340-1348. PubMed ID: 32699034
    [Abstract] [Full Text] [Related]

  • 2. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea.
    Zhang F, Bae SC, Bass D, Chu M, Egginton S, Gordon D, Roth DA, Zheng J, Tanaka Y.
    Ann Rheum Dis; 2018 Mar; 77(3):355-363. PubMed ID: 29295825
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Fifty-Two-Week Randomized, Double-Blind, Placebo-Controlled Study.
    Stohl W, Schwarting A, Okada M, Scheinberg M, Doria A, Hammer AE, Kleoudis C, Groark J, Bass D, Fox NL, Roth D, Gordon D.
    Arthritis Rheumatol; 2017 May; 69(5):1016-1027. PubMed ID: 28118533
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of Belimumab in Children With Systemic Lupus Erythematosus.
    Dimelow R, Ji B, Struemper H.
    Clin Pharmacol Drug Dev; 2021 Jun; 10(6):622-633. PubMed ID: 33245847
    [Abstract] [Full Text] [Related]

  • 5. Organ system improvements in Japanese patients with systemic lupus erythematosus treated with belimumab: A subgroup analysis from a phase 3 randomized placebo-controlled trial.
    Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Roth D.
    Mod Rheumatol; 2020 Mar; 30(2):313-320. PubMed ID: 31199180
    [Abstract] [Full Text] [Related]

  • 6. Phase III, multicentre, randomised, double-blind, placebo-controlled, 104-week study of subcutaneous belimumab administered in combination with rituximab in adults with systemic lupus erythematosus (SLE): BLISS-BELIEVE study protocol.
    Teng YKO, Bruce IN, Diamond B, Furie RA, van Vollenhoven RF, Gordon D, Groark J, Henderson RB, Oldham M, Tak PP.
    BMJ Open; 2019 Mar 20; 9(3):e025687. PubMed ID: 30898822
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of intravenous belimumab in Japanese patients with systemic lupus erythematosus: A subgroup analysis of a phase 3 randomized placebo-controlled trial.
    Tanaka Y, Bass D, Chu M, Egginton S, Ji B, Struemper H, Roth D.
    Mod Rheumatol; 2019 May 20; 29(3):452-460. PubMed ID: 29792370
    [Abstract] [Full Text] [Related]

  • 8. Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial.
    Jones A, Muller P, Dore CJ, Ikeji F, Caverly E, Chowdhury K, Isenberg DA, Gordon C, Ehrenstein MR.
    BMJ Open; 2019 Dec 16; 9(12):e032569. PubMed ID: 31848169
    [Abstract] [Full Text] [Related]

  • 9. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.
    Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF, BLISS-76 Study Group.
    Arthritis Rheum; 2011 Dec 16; 63(12):3918-30. PubMed ID: 22127708
    [Abstract] [Full Text] [Related]

  • 10. The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.
    Wilkinson C, Henderson RB, Jones-Leone AR, Flint SM, Lennon M, Levy RA, Ji B, Bass DL, Roth D.
    Arthritis Res Ther; 2020 May 04; 22(1):102. PubMed ID: 32366280
    [Abstract] [Full Text] [Related]

  • 11. Phase III/IV, Randomized, Fifty-Two-Week Study of the Efficacy and Safety of Belimumab in Patients of Black African Ancestry With Systemic Lupus Erythematosus.
    Ginzler E, Guedes Barbosa LS, D'Cruz D, Furie R, Maksimowicz-McKinnon K, Oates J, Santiago MB, Saxena A, Sheikh S, Bass DL, Burriss SW, Gilbride JA, Groark JG, Miller M, Pierce A, Roth DA, Ji B.
    Arthritis Rheumatol; 2022 Jan 04; 74(1):112-123. PubMed ID: 34164944
    [Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
    Navarra SV, Guzmán RM, Gallacher AE, Hall S, Levy RA, Jimenez RE, Li EK, Thomas M, Kim HY, León MG, Tanasescu C, Nasonov E, Lan JL, Pineda L, Zhong ZJ, Freimuth W, Petri MA, BLISS-52 Study Group.
    Lancet; 2011 Feb 26; 377(9767):721-31. PubMed ID: 21296403
    [Abstract] [Full Text] [Related]

  • 13. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.
    Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA, LBSL02/99 Study Group.
    J Rheumatol; 2014 Feb 26; 41(2):300-9. PubMed ID: 24187095
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of belimumab in paediatric and adult patients with systemic lupus erythematosus: an across-study comparison.
    Brunner HI, Abud-Mendoza C, Mori M, Pilkington CA, Syed R, Takei S, Viola DO, Furie RA, Navarra S, Zhang F, Bass DL, Eriksson G, Hammer AE, Ji BN, Okily M, Roth DA, Quasny H, Ruperto N.
    RMD Open; 2021 Sep 26; 7(3):. PubMed ID: 34531304
    [Abstract] [Full Text] [Related]

  • 15. Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.
    Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D.
    Arthritis Rheumatol; 2018 Jun 26; 70(6):868-877. PubMed ID: 29409143
    [Abstract] [Full Text] [Related]

  • 16. A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus.
    Doria A, Bass D, Schwarting A, Hammer A, Gordon D, Scheinberg M, Fox NL, Groark J, Stohl W, Kleoudis C, Roth D.
    Lupus; 2018 Aug 26; 27(9):1489-1498. PubMed ID: 29807477
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials.
    Strand V, Levy RA, Cervera R, Petri MA, Birch H, Freimuth WW, Zhong ZJ, Clarke AE, BLISS-52 and -76 Study Groups.
    Ann Rheum Dis; 2014 May 26; 73(5):838-44. PubMed ID: 23524886
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Long-term safety and limited organ damage in patients with systemic lupus erythematosus treated with belimumab: a Phase III study extension.
    van Vollenhoven RF, Navarra SV, Levy RA, Thomas M, Heath A, Lustine T, Adamkovic A, Fettiplace J, Wang ML, Ji B, Roth D.
    Rheumatology (Oxford); 2020 Feb 01; 59(2):281-291. PubMed ID: 31302695
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.